One or two 7.5-μg doses of MF59-adjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in adults within 21 days

Granwehr, Bruno
January 2010
ACP Journal Club;1/19/2010, Vol. 152 Issue 1, p7
Academic Journal
The article discusses a study conducted by doctor I. Stephenson and colleagues to know the immunogenicity and safety of a monovalent MF59-adjuvanted influenza A (H1N1) 2009 vaccine. An interim analysis of a randomized controlled trial of 100 adults between the age 18 to 50 years has found that 7.5-mg doses of H1N1 2009 vaccine was immunogenic in healthy adults within 21 days Novel influenza virus infection.


Related Articles

  • Big Drugmakers Start Trials of Swine Flu Vaccines.  // Clinical Infectious Diseases;10/1/2009, Vol. 49 Issue 7, pi 

    The article reports that giant drug manufacturers such as GlaxoSmithKline, Novartis, and Sanofi Aventis have started their clinical trials for the H1N1 swine flu vaccine.

  • Officials look toward fall for clinical data on pandemic vaccines. Traynor, Kate // American Journal of Health-System Pharmacy;9/1/2009, Vol. 66 Issue 17, p1513 

    The article offers an update concerning the clinical trials of monovalent vaccines against the influenza H1N1 virus in the U.S. Robin Robinson, director of the Biomedical Advanced Research and Development Authority (BARDA), that they data on the safety and efficacy of the vaccines will be...

  • Novavax reports positive results from influenza vaccine study.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p8 

    The article reports that biotechnology company Novavax Inc. reports positive results of its two-state pivotal study to evaluate the safety and immunogenicity of its unadjuvanted 2009 A/H1N1 virus-like particle pandemic influenza vaccine. According to the company, data shows that safety and...

  • Dabigatran: An Oral Direct Thrombin Inhibitor.  // OB/GYN Clinical Alert;Feb2010 Pharmacology Watch, p1 

    The article reports on several issues published in "Pharmacological Watch" including H1N1 vaccine dosing and efficacy, intensive lipid lowering in cardiovascular diseases (CVD), results from a Phase 3 study of dabigatran in the U.S. It states that H1N1 is effective for children age 3 and older...

  • Altered Response to A(H1N1)pnd09 Vaccination in Pregnant Women: A Single Blinded Randomized Controlled Trial. Bischoff, Anne Louise; Følsgaard, Nilofar Vahman; Carson, Charlotte Giwercman; Stokholm, Jakob; Pedersen, Louise; Holmberg, Maria; Bisgaard, Amalie; Birch, Sune; Tsai, Theodore F.; Bisgaard, Hans // PLoS Clinical Trials;Apr2013, Vol. 10 Issue 4, Special section p1 

    Background: Pregnant women were suspected to be at particular risk when H1N1pnd09 influenza became pandemic in 2009. Our primary objective was to compare the immune responses conferred by MF59®-adjuvanted vaccine (Focetria®) in H1N1pndO9-naïve pregnant and non-pregnant women. The...

  • 2009 H1N1 Vaccine Safe and Induces Robust Immune Response in People With Asthma.  // Trends in Medical Research;2011, Vol. 6 Issue 2, p145 

    No abstract available.

  • Single jab could be enough for swine flu.  // Independent Nurse;9/7/2009, p4 

    The article reports on initial trial results which indicated that a single jab may be enough to protect patients against the (A) H1N1 swine flu. The trial was conducted by the University of Leicester and Leicester Hospital in England and involved 100 healthy subjects aged 18 to 50 years....

  • Professionals urged to get swine flu jab.  // Independent Nurse;9/21/2009, p10 

    The article reports on the result of a survey concerning the stance of some of health professionals and patients on the issue of swine flu vaccination in Great Britain. The importance of swine flu vaccination is stressed amidst concern that nearly 60 percent of general practitioners will refuse...

  • Despite the scaremongering, a swine flu jab is worthwhile. Fitzpatrick, Michael // Community Care;11/26/2009, Issue 1797, p29 

    The article discusses issues related to using swine flu vaccine. The author says that the vaccine is only a slightly modified version of the familiar seasonal flu vaccine. The author says that limited trials have been made for the efficacy and safety of the swine flu vaccine. Anti-vaccine...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics